Market Cap 26.09B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 10.51
Forward PE 11.67
Profit Margin 16.87%
Debt to Equity Ratio 0.35
Volume 2,115,600
Avg Vol 2,094,556
Day's Range N/A - N/A
Shares Out 146.70M
Stochastic %K 97%
Beta 0.13
Analysts Sell
Price Target $179.61

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
dogDazeSummer
dogDazeSummer Jan. 6 at 9:45 PM
$VTYX in discussions with $LLY on oral anti inflammatory $1B deal 52 week low .84 52 week high $16.28, now https://www.wsj.com/health/pharma/eli-lilly-nears-deal-for-biotech-ventyx-3bc666d2?st=77K3Z8&reflink=article_copyURL_share Can $IFRX catch a bid at JPM biotech conference? $AMGN $BIIB paid $1B and $4B Let’s go Niels, it’s been a long road, time for something sweeeeet ..
1 · Reply
JamesTate846
JamesTate846 Jan. 6 at 5:27 PM
$FE $CQP $BIIB $AVB $SHG Nicely finalized
0 · Reply
Chartist0_0
Chartist0_0 Jan. 6 at 2:49 PM
$BIIB 250$ in March
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 6 at 11:36 AM
Enter: $BIIB Calls Strike Price: $178 Expiry Date: JAN 30 2026 Buy in Price: $6.00 - $6.30 Sell Price: $10.56 Profit : +76% (Turn every $1 into $1.76) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 5 at 4:09 PM
$BIIB Current Stock Price: $172.79 Contracts to trade: $170 BIIB Jan 09 2026 Call Entry: $3.70 Exit: $5.77 ROI: 56% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Jan. 5 at 2:20 PM
$NMRA Positives: Premium pricing power in 'Anxiety' niche. Clear differentiator vs $LUND (Rexulti) on sedation. Negatives: Hyponatremia = Specialty only (No PCP uptake). BID dosing hurts adherence. Watch $LUND $OTS $BIIB $LLY for competitive context. #Pharma #MarketAccess #Alzheimers https://www.clinicaltrialsdaily.com/nmra-511-for-anxiety-driven-ad-agitation/
0 · Reply
Quantumup
Quantumup Jan. 5 at 2:13 PM
Chardan transferred coverage on $STOK w/ a Buy rating and a $35 PT. $PRAX $BIIB $UCBJY UCBJF $JAZZ Cantor reiterated Stoke Therapeutics at an Overweight rating. Here's what Chardan and Cantor had to say in there notes to investors: https://x.com/Quantumup1/status/2008178701653901498?s=20
0 · Reply
Quantumup
Quantumup Jan. 5 at 12:31 PM
Leerink transferred coverage on $LRMR at an Outperform rating and a $12 PT. $BIIB $LXEO $PTCT Leerink said: Bottom Line: We are transferring coverage of LRMR with an Outperform rating and a $12 PT. As we approach LRMR's regulatory discussion and open-label study updates in 1Q26 ahead of their plans to submit their BLA filing in 2Q26, there are a lot of questions for this program so we are taking a fresh look at it and the stock's potential reaction to upcoming updates. After speaking with several MEDACorp specialists and taking many factors into consideration, we believe that the FDA could continue to see a favorable benefit/risk profile for nomlabofusp, especially among patients with severe disease. Thus, we are maintaining an Outperform Rating, although we are lowering our PT to $12.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 4 at 5:45 PM
Enter: $BIIB Calls Strike Price: $180 Expiry Date: JAN 30 2026 Buy in Price: $4.47 - $6.30 Sell Price: $7.06 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
AnalyticalOne
AnalyticalOne Jan. 2 at 6:56 PM
2 · Reply
Latest News on BIIB
AI Stocks Are Taking a Beating. What to Buy Instead.

Nov 21, 2025, 1:13 PM EST - 6 weeks ago

AI Stocks Are Taking a Beating. What to Buy Instead.

AKAM AMZN EXPE LLY


Biogen Completes Acquisition of Alcyone Therapeutics

Nov 14, 2025, 4:05 PM EST - 7 weeks ago

Biogen Completes Acquisition of Alcyone Therapeutics

IONS


Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 9:16 PM EDT - 2 months ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript


Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 9, 2025, 10:54 AM EDT - 3 months ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again


BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 3, 2025, 8:50 AM EDT - 3 months ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?


dogDazeSummer
dogDazeSummer Jan. 6 at 9:45 PM
$VTYX in discussions with $LLY on oral anti inflammatory $1B deal 52 week low .84 52 week high $16.28, now https://www.wsj.com/health/pharma/eli-lilly-nears-deal-for-biotech-ventyx-3bc666d2?st=77K3Z8&reflink=article_copyURL_share Can $IFRX catch a bid at JPM biotech conference? $AMGN $BIIB paid $1B and $4B Let’s go Niels, it’s been a long road, time for something sweeeeet ..
1 · Reply
JamesTate846
JamesTate846 Jan. 6 at 5:27 PM
$FE $CQP $BIIB $AVB $SHG Nicely finalized
0 · Reply
Chartist0_0
Chartist0_0 Jan. 6 at 2:49 PM
$BIIB 250$ in March
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 6 at 11:36 AM
Enter: $BIIB Calls Strike Price: $178 Expiry Date: JAN 30 2026 Buy in Price: $6.00 - $6.30 Sell Price: $10.56 Profit : +76% (Turn every $1 into $1.76) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 5 at 4:09 PM
$BIIB Current Stock Price: $172.79 Contracts to trade: $170 BIIB Jan 09 2026 Call Entry: $3.70 Exit: $5.77 ROI: 56% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Jan. 5 at 2:20 PM
$NMRA Positives: Premium pricing power in 'Anxiety' niche. Clear differentiator vs $LUND (Rexulti) on sedation. Negatives: Hyponatremia = Specialty only (No PCP uptake). BID dosing hurts adherence. Watch $LUND $OTS $BIIB $LLY for competitive context. #Pharma #MarketAccess #Alzheimers https://www.clinicaltrialsdaily.com/nmra-511-for-anxiety-driven-ad-agitation/
0 · Reply
Quantumup
Quantumup Jan. 5 at 2:13 PM
Chardan transferred coverage on $STOK w/ a Buy rating and a $35 PT. $PRAX $BIIB $UCBJY UCBJF $JAZZ Cantor reiterated Stoke Therapeutics at an Overweight rating. Here's what Chardan and Cantor had to say in there notes to investors: https://x.com/Quantumup1/status/2008178701653901498?s=20
0 · Reply
Quantumup
Quantumup Jan. 5 at 12:31 PM
Leerink transferred coverage on $LRMR at an Outperform rating and a $12 PT. $BIIB $LXEO $PTCT Leerink said: Bottom Line: We are transferring coverage of LRMR with an Outperform rating and a $12 PT. As we approach LRMR's regulatory discussion and open-label study updates in 1Q26 ahead of their plans to submit their BLA filing in 2Q26, there are a lot of questions for this program so we are taking a fresh look at it and the stock's potential reaction to upcoming updates. After speaking with several MEDACorp specialists and taking many factors into consideration, we believe that the FDA could continue to see a favorable benefit/risk profile for nomlabofusp, especially among patients with severe disease. Thus, we are maintaining an Outperform Rating, although we are lowering our PT to $12.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 4 at 5:45 PM
Enter: $BIIB Calls Strike Price: $180 Expiry Date: JAN 30 2026 Buy in Price: $4.47 - $6.30 Sell Price: $7.06 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
AnalyticalOne
AnalyticalOne Jan. 2 at 6:56 PM
2 · Reply
CrispDry
CrispDry Jan. 2 at 6:37 PM
$DJT why does he keep drawing attention to the fact that he has massive cognitive health issues ? He’s had 3 cognitive tests already in his first year in office. This is NOT NORMAL. It makes it more apparent his hand wounds are from Leqembi infusions for early Alzheimer’s $RUM $BIIB $ESALY
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 2 at 11:52 AM
Enter: $BIIB Calls Strike Price: $178 Expiry Date: JAN 23 2026 Buy in Price: $4.40 - $6.00 Sell Price: $7.39 Profit : +68% (Turn every $1 into $1.68) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
WilliamDoepke338
WilliamDoepke338 Jan. 1 at 3:30 PM
$FE $CQP $BIIB $AVB $SHG Nicely finalized
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 31 at 6:41 PM
Enter: $BIIB Calls Strike Price: $178 Expiry Date: JAN 23 2026 Buy in Price: $4.88 - $5.70 Sell Price: $9.96 Profit : +104% (Turn every $1 into $2.04) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
topstockalerts
topstockalerts Dec. 29 at 4:27 PM
After two years of underperformance, healthcare stocks broadly matched the market in 2025 as investors rotated out of technology. The outlook for 2026 remains mixed, with fundamentals still pressured by patent expirations, Medicare Advantage challenges, and political risks, but several key themes could drive performance. Alzheimer’s research is regaining attention, led by Eli Lilly’s Trailblazer-ALZ-3 trial testing whether early intervention can delay disease onset. A positive outcome could reshape treatment strategies and significantly expand the market. UnitedHealth Group is also in focus after its shares collapsed in spring 2025 due to Medicare Advantage problems; management is targeting a return to double-digit growth starting in 2027, though execution will be closely watched. Another major theme is the launch of oral GLP-1 weight-loss drugs from Lilly and Novo Nordisk. $LLY $BIIB $UNH $MDT $SPX
0 · Reply
hegdaom
hegdaom Dec. 29 at 12:56 PM
$AGIO basically some clowns here lost in it. sold too early. now supposedly they are smart after LOSING their shirts? gimme a break!!!! $LLY $PFE $MRK $BIIB
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 29 at 12:01 PM
Enter: $BIIB Calls Strike Price: $178 Expiry Date: JAN 23 2026 Buy in Price: $6.30 - $7.50 Sell Price: $15.53 Profit : +107% (Turn every $1 into $2.07) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
OnlyFibs
OnlyFibs Dec. 28 at 4:06 AM
The $BIIB tape is officially whispering what the 82% LEQEMBI growth already proved. We’ve successfully flipped the yearly resistance and are now back-testing $174 as the new structural floor. With Schonfeld stacking millions of shares and a $230 median target, the risk-reward here is completely skewed to the upside. Bull Trigger: Reclaiming the $177.12 pivot ignites the run back toward the $260 analyst high. Bear Floor: Defending the $174.80 volume shelf. If the $172 macro shelf snaps, the thesis resets. Smart money is loading the "Alzheimer's King" while the sector bears miss the 50% valuation discount. 🚢💎 Zeroing in on the 8h compression as $BIIB successfully defends its primary rising trendline at $175. Between the $4.8B Amicus acquisition and the record $1.2B quarterly cash flow, the fundamental floor is getting very loud. RSI is curling from its recent peak—the spring is officially loaded.#hovdid
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 27 at 11:59 AM
Enter: $BIIB Calls Strike Price: $180 Expiry Date: JAN 16 2026 Buy in Price: $4.05 - $4.25 Sell Price: $6.03 Profit : +49% (Turn every $1 into $1.49) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Chartist0_0
Chartist0_0 Dec. 26 at 8:34 PM
$BIIB long.
0 · Reply
Chartist0_0
Chartist0_0 Dec. 26 at 4:34 PM
$BIIB 245$ mid March.
0 · Reply
OnlyFibs
OnlyFibs Dec. 26 at 4:41 AM
The Alzheimer’s Moat is Widening: $BIIB is Coiling for a 2026 Rip 🧠🚀 The $BIIB tape is officially a game of institutional front-running. While retail sleeps, RBC Capital just tagged this as a top 2026 pick with a $210 target—citing a Leqembi growth curve that's finally hitting the vertical. With 95% institutional ownership and new QALSODY data printing green, the value gap is closing fast. Bull Key Levels: Clearing the $182.12 pivot ignites the run back toward the 52-week highs at $185.17. Bear Key Levels: If we lose the $172.90 structural floor, the trend resets toward the 50-day MA at $164.72. Smart money is loading the neurological floor while the "Lilly Sympathy" play brews for Q1. 🚢💎 #hovdid
0 · Reply